

## 2015 Financial Calendar

**Lyon, France, March 16, 2015** – POXEL (Euronext - FR0012432516), an independent French biopharmaceutical company focused on the development of antidiabetic drugs, today announces its schedule for the publication of financial information for 2015.

Événement	Date *
2014 Full-Year Sales	March 16, 2015
2014 Full-Year Financial statements	April 30, 2015
2015 Q1 Sales	May 5, 2015
Annual Shareholders' Meeting	June 16, 2015
2015 Q2 Sales	July 15, 2015
2015 June 30 <sup>th</sup> , Financial statements	August 31, 2015
2015 Q3 Sales	October 22, 2015
2015 Full-Year Sales	January 28, 2016

\* Subject to modification. Press releases are published after market closes.

### About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, [www.poxel.com](http://www.poxel.com))

### Contacts

#### Investor / Media Relations - France

NewCap  
Florent Alba/Nicolas Merigeau  
[poxel@newcap.fr](mailto:poxel@newcap.fr)  
+33 1 44 71 98 55

#### Investor / Media Relations – EU/US

MacDougall Biomedical Communications  
Gretchen Schweitzer or Anca Alexandru  
[aalexandru@macbiocom.com](mailto:aalexandru@macbiocom.com)  
+49 89 2424 3494